22.2 C
New York
Monday, June 8, 2026

Tag: X

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

Corgi Launches Suite of Six Fixed Income ETFs on Cboe BZX, Capping a Week of 50 Fund Launches

Corgi lists CGOV, CBIL, CUST, CIEI, CIVG, and CHYG - offering Treasury and corporate bond exposure across the yield curve at an expense ratio...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

Emerging Crypto Projects Focus on Infrastructure as AI Narrative Evolves Beyond Simple Token Hype

SACRAMENTO, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- The intersection of artificial intelligence and blockchain technology is entering a critical maturation phase, where speculative narratives are increasingly being replaced by projects that prioritize tangible network infrastructure. Solana Unchained stands at the forefront of this shift, constructing a decentralized environment where native tokens are not merely held for appreciation, but are required to power essential software utilities. 

Nominations Open for Organic Grower Summit’s 2026 Grower of the Year Award

Nominations now open for the 2026 Organic Grower of the Year Award at Organic Grower Summit. John Deere sponsors award honoring organic farming innovation.

South Coast AQMD Approves Largest-Ever Award for Zero-Emission Switcher Locomotives

$250 million investment for clean technologies, will reduce 600 tons of emissions each yearDIAMOND BAR, Calif., June 5, 2026 /PRNewswire/ -- Today, the South...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsX